JP2017515847A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017515847A5 JP2017515847A5 JP2016567517A JP2016567517A JP2017515847A5 JP 2017515847 A5 JP2017515847 A5 JP 2017515847A5 JP 2016567517 A JP2016567517 A JP 2016567517A JP 2016567517 A JP2016567517 A JP 2016567517A JP 2017515847 A5 JP2017515847 A5 JP 2017515847A5
- Authority
- JP
- Japan
- Prior art keywords
- herpes simplex
- simplex virus
- oncolytic
- oncolytic herpes
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000174 oncolytic effect Effects 0.000 claims description 26
- 241000700584 Simplexvirus Species 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 201000011510 cancer Diseases 0.000 claims description 13
- 229940123877 Aurora kinase inhibitor Drugs 0.000 claims description 9
- 239000003719 aurora kinase inhibitor Substances 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 101150076998 ICP34.5 gene Proteins 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 241000700589 Herpes simplex virus (type 1 / strain 17) Species 0.000 claims description 3
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims 1
- 244000309459 oncolytic virus Species 0.000 description 15
- ZLHFILGSQDJULK-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC)=C1 ZLHFILGSQDJULK-UHFFFAOYSA-N 0.000 description 1
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1408297.8A GB201408297D0 (en) | 2014-05-12 | 2014-05-12 | Treatment of cancer |
| GB1408297.8 | 2014-05-12 | ||
| PCT/GB2015/051347 WO2015173544A1 (en) | 2014-05-12 | 2015-05-07 | Oncolytic virus and aurora kinase inhibitor for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017515847A JP2017515847A (ja) | 2017-06-15 |
| JP2017515847A5 true JP2017515847A5 (https=) | 2018-06-14 |
Family
ID=51032548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016567517A Pending JP2017515847A (ja) | 2014-05-12 | 2015-05-07 | がんの治療のための腫瘍溶解性ウイルスおよびオーロラキナーゼ阻害薬 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20170071991A1 (https=) |
| EP (1) | EP3142677A1 (https=) |
| JP (1) | JP2017515847A (https=) |
| CN (1) | CN106535940A (https=) |
| GB (1) | GB201408297D0 (https=) |
| WO (1) | WO2015173544A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200085890A1 (en) * | 2016-07-29 | 2020-03-19 | Ohio State Innovation Foundation | Expression of pten-long with ocolytic viruses |
| US11357776B2 (en) | 2016-10-28 | 2022-06-14 | Acetylon Pharmaceuticals, Inc. | Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof |
| CN110869052A (zh) * | 2016-12-23 | 2020-03-06 | 维图生物制剂公司 | 癌症的治疗 |
| CN109576231B (zh) | 2017-09-28 | 2022-03-25 | 北京康万达医药科技有限公司 | 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途 |
| CN109985239B (zh) * | 2017-12-29 | 2024-10-18 | 广州威溶特医药科技有限公司 | 极光激酶抑制剂和甲病毒在制备抗肿瘤药物的应用 |
| CN116004567A (zh) * | 2022-12-07 | 2023-04-25 | 北京大学 | 极光激酶b基因k202突变及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6309274B2 (ja) * | 2011-03-11 | 2018-04-11 | ターンストーン・リミテッド・パートナーシップ | ヒストンデアセチラーゼ阻害剤を含むワクチン接種法 |
| WO2012135641A2 (en) * | 2011-03-30 | 2012-10-04 | H. Lee Moffitt Cancer Center And Research Institute | Aurora kinase inhibitors and methods of making and using thereof |
| US9056133B2 (en) * | 2011-05-25 | 2015-06-16 | Cti-S.A. | Pharmaceutical kit and method for treating cancer |
-
2014
- 2014-05-12 GB GBGB1408297.8A patent/GB201408297D0/en not_active Ceased
-
2015
- 2015-05-07 US US15/310,556 patent/US20170071991A1/en not_active Abandoned
- 2015-05-07 EP EP15721808.2A patent/EP3142677A1/en not_active Withdrawn
- 2015-05-07 CN CN201580038192.8A patent/CN106535940A/zh active Pending
- 2015-05-07 JP JP2016567517A patent/JP2017515847A/ja active Pending
- 2015-05-07 WO PCT/GB2015/051347 patent/WO2015173544A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017515847A5 (https=) | ||
| BR112022009571A2 (pt) | Uso de inibidor de fak na preparação de um fármaco para tratar tumores que têm mutação nras | |
| JP5718377B2 (ja) | パルボウイルスをｈｄａｃ阻害剤と併用して使用する癌治療 | |
| ES2762250T3 (es) | Tratamiento combinado del cáncer | |
| JP2016518387A5 (https=) | ||
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| BR112015029918A2 (pt) | uso de alta dose de pridopidina para tratar a doença de huntington | |
| JP2018109022A5 (https=) | ||
| MX2011013467A (es) | Metodo para tratar un paciente que corre el riesgo de desarollar una ulcera asociada a antiinflamatorio no esteroide (aine). | |
| EA201590166A1 (ru) | Комбинированная терапия для лечения рассеянного склероза | |
| CN111344398A (zh) | 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途 | |
| JP2020521797A5 (https=) | ||
| BR112014027010A2 (pt) | uso de laquinimod de alta dose para tratamento de esclerose múltipla | |
| BR112015030578A2 (pt) | combinações farmacêuticas | |
| HK1202776A1 (en) | Use of laquinimod for treating crohn's disease patients who failed first-line anti-tnf therapy | |
| BR112022003220A2 (pt) | Uma composição farmacêutica para tratar câncer usada para um paciente tendo marcador genético específico | |
| Belin et al. | An oncolytic vaccinia virus expressing the human sodium iodine symporter prolongs survival and facilitates SPECT/CT imaging in an orthotopic model of malignant pleural mesothelioma | |
| JP2016519107A5 (https=) | ||
| Ady et al. | Oncolytic gene therapy with recombinant vaccinia strain GLV-2b372 efficiently kills hepatocellular carcinoma | |
| JP2014534229A5 (https=) | ||
| BR112015030664A2 (pt) | combinação farmacêutica de um inibidor de pi3k e um agente desestabilizador de microtúbulos | |
| HRP20231299T1 (hr) | Inhibitori pi3k p-delta 110 za uporabu u isporuci virusa u liječenju raka | |
| JP2020501589A5 (https=) | ||
| BR112014004339A2 (pt) | suspensão oral | |
| BR112016014903A8 (pt) | combinações farmacêuticas que compreendem um inibidor de pi3k, seu uso, sua preparação combinada, e embalagem comercial |